Side-population (SP) analysis identifies precursor cells in normal and malignant tissues. Cells with this phenotype have increased resistance to many cytotoxic agents, and may represent a primary drug-resistant population in malignant diseases. To discover whether drug-resistant malignant SP cells are nonetheless sensitive to immune-mediated killing, we first established the presence of a malignant CD5 þ CD19 þ SP subset in the blood of 18/21 subjects with B-cell chronic lymphocytic leukemia (B-CLL). We examined the fate of these cells in six of these individuals who received autologous human CD40 ligand and interleukin-2 (hCD40L/IL-2) genemodified tumor cells as part of a tumor vaccine study. Vaccinated patients showed an increase in B-CLL-reactive T cells followed by a corresponding decline in circulating CD5 þ CD19 þ SP cells. T-cell lines and clones generated from vaccinated patients specifically recognized B-CLL SP tumor cells. Elimination of SP cells is likely triggered by their increased expression of target antigens, such as receptor for hyaluronan-mediated motility (RHAMM), after stimulation of the malignant cells by hCD40L, as CD8 þ RHAMM-specific T cells could be detected in the peripheral blood of immunized patients and were associated with the decline in B-CLL SP cells. Hence, malignant B cells with a primary drug-resistant phenotype can be targeted by T-cell-mediated effector activity after immunization of human subjects.
Introduction
Differential efflux of fluorescent vital dyes, such as Hoechst 33342 (Sigma-Aldrich, St Louis, MO, USA), can distinguish a distinct side population (SP) on flow cytometric analysis of animal and human bone marrow cells. 1, 2 Cells isolated by this technique can exert an effect as multi-lineage, repopulating hematopoietic stem cells in engraftment and serial transplantation studies.
1 SP cells have subsequently been identified in hematopoietic malignancies, including acute myeloid leukemia 3 and myeloma, 4 as well as in many solid tumors, including neuroblastoma, 5 and cancers of ovary, 6 breast, 7 gastrointestinal tract 8 and lung. 9 Tumor-derived SP cells show biological similarities to hematopoietic stem cells, including superior proliferative and tumor-initiating capacity, 10 and the ability to produce SP and non-SP progeny. 5 Moreover, their biological characteristics render tumor SP cells more resistant to chemoand radiotherapy than their non-SP counterparts. 11, 12 The SP cell phenotype itself seems to be due to an increased activity of transporter proteins, including multi-drug resistance protein 1 and other ATP-binding cassette (ABC) transporters, 13, 14 which accelerate the export of Hoechst dyes. These same transporter proteins also reduce the intracellular concentrations, and thus the effectiveness, of many commonly used chemotherapeutic drugs. 4, 5, 9 Because tumor SP cells may therefore have the ability to resist common chemotherapeutic agents, this subpopulation may contribute to disease persistence or relapse after treatment, irrespective of whether or not SP cells have a role as tumor progenitors.
Although the SP phenotype may protect cells from many conventional cytotoxic drugs, their unique characteristics also may make them specifically targetable by the immune system. 15, 16 If this were so, immunotherapy might be combined with conventional treatments for optimal anti-tumor activity. We now establish that patients with B-cell chronic lymphocytic leukemia (B-CLL) have a circulating malignant population with an SP phenotype, and that a T-cell immune response generated by these subjects during a course of immunization with human CD40 ligand (hCD40L) and interleukin-2 (IL-2) 17 gene-modified autologous tumor cells leads to the selective disappearance of the SP subset of cells from their circulation, while leaving total circulating B-CLL cell numbers unaffected.
Materials and methods

Detection of SP cells in peripheral blood samples from B-CLL patients
Blood was obtained from 21 patients with B-CLL who had blood collected for vaccine studies (see Table 1 for disease stage) or healthy donors according to the approved protocols of the institutional review board.. Peripheral blood mononuclear cells (PBMCs) from B-CLL patients were cultured overnight at 37 1C in RPMI supplemented with 10% fetal bovine serum, 2 mM L-glutamine and 20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) (SP buffer). Cells were then counted and diluted to 1 Â 10 6 cells/ml in SP buffer and labeled with 5 mg/ml Hoechst 33342 dye (Sigma-Aldrich) and incubated for 90 min at 37 1C. After incubation, cells were washed and stained with CD5 fluorescein isothiocyanate (FITC) and CD19 phycoerythrin (PE) antibodies (BD Biosciences, San Jose, CA, USA) for 30 min on ice. Cells were washed again and resuspended in ice-cold phosphate-buffered saline containing 2 mg/ml propidium iodide (Sigma) to exclude dead cells. We used a MoFlo high-speed cell sorter (MoFlo; Cytomation, Fort Collins, CO, USA) for cell analysis and sorting, in which SP and non-SP cells were characterized as previously described.
1,2 To validate the SP phenotype, the Ca 2 þ channel blocker, Verapamil (50 mM) (Sigma) was used. 1 
Analysis of SP cells and anti-tumor immune responses in blood samples from patients receiving autologous B-CLL tumor vaccine
Between 2002 and 2005, six of the B-CLL patients with an SP subset received 3-8 subcutaneous injections of autologous B-CLL tumor cells that were modified to express CD40L and IL-2 on an approved study (CLIMAT) by the institutional review board Recombinant DNA Advisory Committee and US Food and Drug Administration. 17 PBMCs and B-CLL cells were collected from these patients before, during and after immunization, and viably frozen and stored in liquid nitrogen. We used these samples to measure the fate of SP B-CLL cells of the patients after immunization and to measure T-cell-mediated immune responses directed to SP and non-SP cells. In addition, 15 additional patient samples collected for vaccine manufacture on this study or follow-up studies (CLIPA or PRIMAL) were also analyzed for SP frequency ( Table 1) .
Effect of fludarabine on B-CLL SP cells
To determine the resistance of B-CLL SP cells to fludarabine, we examined SP frequencies in samples cultured with and without fludarabine.
5 B-CLL PBMC samples were incubated with and without 50 mM fludarabine (Sigma) and then cultured for 48 h and analyzed using fluorescence-activated cell-sorting for SP cell frequency and apoptosis/cell death using an Annexin-V/PI kit (BD Bioscience).
RHAMM gene expression analysis of SP and non-SP B-CLL tumor cells
To examine the effects of CD40L activation on receptor for hyaluronan-mediated motility (RHAMM) expression, B-CLL cells were either cultured overnight at 37 1C in media alone or stimulated for 24 h with 10 mg/ml trimeric recombinant human CD40L and 2 mg/ml trimerization enhancer (Alexis Biochemicals, Lausen, Switzerland). After stimulation, cells were stained and sorted into CD5 þ CD19 þ SP or non-SP and RNA was extracted using RNeasy Micro Plus kits (Qiagen, Valencia, CA, USA). Purified RNA was then analyzed by One-Step reverse transcriptase-PCR (Qiagen) using gene-specific primers for RHAMM, survivin (BIRC5), fibromodulin, murine double minute-2 and glyceraldehyde 3-phosphate dehydrogenase (SA Biosciences, Frederick, MD, USA).
Generation of B-CLL-reactive T-cell lines and clones Generation of B-CLL-specific T-cell lines and clones from patient blood. To generate B-CLL-specific T-cell lines against autologous tumor cells, CD8 þ T cells were isolated from PBMCs by high-speed cell sorting (MoFlo) and then stimulated with irradiated (40 Gy), autologous hCD40L-activated B-CLL tumor cells (1:10 responder to stimulator ratio) in 45% RPMI-1640, 45% Click (Eagle Ham amino acids; Irvine Scientific, Santa Anna, CA, USA), 2 mM GlutaMAX-1 and 5% human AB serum (Valley Biomed, Winchester, VA, USA), referred to hereafter as T-cell media (TCM-AB), supplemented with 10 ng/ml of IL-7, IL-12 and IL-21 (R&D Systems, Minneapolis, MN, USA). After 7 days, the cultures were restimulated with hCD40-activated B-CLL tumor cells, and media were supplemented with 50 U/ml IL-2 (Proleukin; Chiron, Emeryville, CA, USA). The T-cell lines were expanded by weekly restimulation in the presence of IL-2. CD8 þ T-cell clones were generated by limiting dilution, plated at 0.3, 1 or 3 cells per well in 96-well plates and cultured with autologous, CD40-activated B-CLL tumor cells in the presence of 100 U/ml IL-2. After 2 weeks, wells that possessed proliferating T cells were tested against autologous B-CLL tumor cells for specificity using interferon-g (IFN-g) enzyme-linked immunosorbent spot (ELIspot) assays. Positive clones were subsequently expanded by weekly stimulation with hCD40L-activated autologous tumor cells.
Generation of RHAMM-specific T-cell lines from HLA-A2-positive B-CLL patients. To generate RHAMM-specific Elimination of SP B-CLL with hCD40L/IL-2 tumor vaccine AE Foster et al T cells, T antigen-presenting cells (TAPCs) were used to stimulate CD8 þ T cells isolated from vaccinated patients using stored samples from weeks 2 through 10 after immunization. To produce TAPCs, PBMCs were activated on non-tissue-culturetreated plates pre-coated with 1 mg/ml anti-CD3 (OKT3; Ortho Pharmaceuticals, Raritan, NJ, USA) and anti-CD28 (Pharmingen, San Diego, CA, USA) in TCM-AB containing 100 U/ml IL-2. 18 After 3 days, activated T cells were harvested and expanded in IL-2-supplemented media. Before use, TAPCs were reactivated on anti-CD3/anti-CD28 plates for 48 h and pulsed with 1 mg/ml ILS peptide (ILSLELMKL; Genemed Synthesis, San Antonio, TX, USA), a human leukocyte antigen (HLA)-A2-restricted peptide derived from RHAMM.
19 CD8 þ T-cell responders were then stimulated at a ratio of 1:10, TAPC to responder cells, with irradiated (30 Gy), peptide-pulsed TAPC in media supplemented with IL-7, IL-12 and IL-21, as above. After 1 week of stimulation, T-cell cultures were expanded by restimulation with activated, peptide-pulsed TAPCs in TCM-AB supplemented with IL-2.
Analysis of B-CLL T-cell specificity and frequency
The reactivity of T-cell lines and clones against B-CLL SP/non-SP target cells and to ILS peptide were assessed using IFN-g ELIspot assays as previously described. 20 For analysis of T-cell reactivity against tumor cells, 1 Â To analyze the frequency of ILS-specific CD8 þ T cells in patient PBMCs, these cells were stained with HLA-A2-restricted, ILSLELMKL-specific pentamer (ProImmune, Bradenton, FL, USA) and Fluorotag phycoerythrin in combination with CD3 peridinin chlorophyll protein (PerCP) and CD8 fluorescein isothiocyanate (FITC, BD), and 1 million events were acquired to visualize sufficient CD3
T-cell-tumor coculture assays
We used coculture assays with ILS-specific T cells generated from the peripheral blood of HLA-A2 þ B-CLL patients to determine whether ILS-specific T cells could eliminate B-CLL SP cells. B-CLL SP cells from peripheral blood were plated in triplicate at 2 Â 10 6 cells per well in SP buffer in 24-well plates, and cultured in media alone, with 1 Â 10 6 ILS-specific T cells or in combination with T cells and soluble CD40L trimerizer as described above. After 48 h, the cells were harvested and analyzed for SP frequency.
Statistics
Student's t-test was used for statistical analyses of functional differences between study groups. The P-values of o0.05 were considered statistical significant. Error bars in all panels represent s.e.m.
Results
Distinct CD5
þ CD19 þ SP phenotype in primary B-CLL tumor samples
PBMCs from 21 patients with B-CLL (Table 1 ) and 5 healthy donors were labeled with Hoechst 33342, and CD5 and CD19 antibodies and then analyzed using flow cytometry for the presence of SP cells (Figure 1a) . A distinct CD5 þ CD19 þ SP phenotype was detectable in the peripheral blood of 18 of 21 (85%) patient samples. We were unable to detect SP cells in ungated PBMCs from normal donors (n ¼ 5), indicating that SP is confined to malignant B-CLL cells (Figure 1b) . In this patient cohort, the median frequency of SP in the positive samples was 0.22% (range 0.02-2.17%). SP frequency was reduced by co-incubation with the calcium channel blocker Verapamil (n ¼ 3; Po0.001), confirming that the SP phenotype was a result of active dye efflux (Figures 1c and d) . These data show that the peripheral blood of B-CLL patients frequently contains a minor subpopulation of B-CLL tumor cells that are capable of expelling Hoechst dye.
-CLL SP cells by fludarabine
The SP phenotype is attributed to the expression of ATP-binding cassette (ABC) transporter proteins, including ABCG2 and multi-drug resistance protein 1, 13, 14 and can directly contribute to resistance of tumor cells to chemotherapy agents. 5 SP cells are also more resistant to apoptosis through transporter-independent mechanisms, including increased expression of pro-survival factors 12 or DNA repair enzymes, 21 implying that B-CLL SP cells may be resistant to commonly used agents even when these are not substrates for ABC transporter proteins. Because fludarabine is so commonly used for the treatment of B-CLL, we incubated B-CLL isolated from PBMCs with and without fludarabine and analyzed whether SP B-CLL cells became selectively enriched. Figures 2a and b show that incubation of B-CLL cells with 50 mM fludarabine concentration enriches SP cells after 48 h (n ¼ 4; P ¼ 0.02). In addition, analysis of SP and non-SP using Annexin-V in B-CLL samples cultured in media alone or with fludarabine showed that SP cells showed less apoptosis than bulk tumor cells (non-SP) after 48 h (P ¼ 0.04) (Figures 2c and d) . Interestingly, SP cells in control cultures also underwent less apoptosis than bulk tumor cells (P ¼ 0.004), suggesting that SP cells are generally more resistant to cell death than non-SP. Overall, these data indicate that SP cells are more resistant to apoptosis induced by fludarabine.
Subcutaneous immunization with CD40L/IL2-expressing B-CLL cells decreases the frequency of tumor SP cells in peripheral blood
Although the SP phenotype is associated with cytotoxic drug resistance, this characteristic should not preclude elimination by immunotherapies that target tumor-associated antigens (TAAs). We previously reported a study of B-CLL patients who received subcutaneous injections of autologous tumor cells expressing transgenic IL-2 and hCD40L over 3 months. 17 In this study, tumor-specific Th1 and Th2 cells responded against bulk (that is, primarily non-SP) autologous tumor, but we observed no significant fall in circulating B-CLL counts. Having detected B-CLL SP cells before immunization in six patients from this study (Table 1) , we re-analyzed these patient samples to determine whether our immunization strategy did in fact have anti-tumor activity that was restricted to the B-CLL SP component, as this would not have been detected in our initial analyses of the effects of the treatment on the bulk tumor population. We did indeed observe a consistent and substantive reduction in CD5 þ CD19 þ SP cells in the peripheral blood of vaccinated patients (Figures 3a and b) , which was associated with a rise in B-CLL-specific immunity during the vaccine treatment (Figure 3b) . Hence, the grouping of samples into three bins, (1) before vaccine (0-2 weeks), (2) during vaccination (2-10 weeks) and (3) after vaccination (weeks 10 þ ), showed a significant decrease in SP frequency associated with a concomitant significant increase in an anti-SP T-cell immune response (Figures 3c and d) . Once the course of immunization ended, however, B-CLL SP cell numbers progressively returned to pre-treatment levels as the T-cell response dwindled (Figure 3b) , supporting a causal relationship between the level of the T-cell immune response and the frequency of B-CLL SP cells, and suggesting that the anti-tumor effects of the B-CLL-directed T-cell response are restricted to the SP subset of cells.
Recognition of B-CLL tumors by T cells after vaccination
As B-CLL-specific T-cell immunity generated by hCD40L/IL-2 autologous tumor immunization was associated with a significant decrease in CD5 þ CD19 þ SP cells, we analyzed whether tumor-specific T cells isolated from the peripheral blood of vaccinated patients could specifically recognize B-CLL SP cells. We generated CD8
þ B-CLL-specific T cells from PBMCs of immunized patients by consecutive stimulation with hCD40L-activated autologous tumor cells. 17 We were able to generate B-CLL-specific T cells from PBMCs collected after vaccination (weeks 4 and 10), but not from pre-vaccine samples, indicating that patients had more frequent or more reactive precursors of B-CLL-specific T cells after their vaccine regimen than before (Figure 4a ). IFN-g production by B-CLL-stimulated CD8 þ T-cell lines was inhibited by the MHC class I blocking antibody W6/32, indicating that specific recognition of autologous B-CLL tumors is mediated through T-cell receptor-MHC class I interaction (Figure 4b ). To determine whether these B-CLL activated T cells could also recognize SP B-CLL cells,
þ SP phenotype is present in B-CLL patient peripheral blood. Samples collected from B-CLL patients were stained with Hoechst 33342 dye followed by antibody and propidium iodide labeling. Cells were gated on either SP or non-SP and examined for expression of CD5 and CD19, showing that both populations are positive for CD5 and CD19 in circulating PBMCs (a). (b) PBMCs collected from 21 B-CLL patients and 5 normal donors were analyzed for the presence of CD5 þ CD19 þ SP cells. In all, 18/21 B-CLL samples contained SP-positive cells, whereas none of the normal PBMCs had the SP subset (Po0.05). To verify that the SP phenotype observed in B-CLL tumor samples was produced by efflux of Hoechst dye (c, d), staining was performed in the presence of 50 mM Verapamil, and it indicated that the SP formation was blocked with Verapamil treatment (P ¼ 0.001).
Elimination of SP B-CLL with hCD40L/IL-2 tumor vaccine
AE Foster et al autologous B-CLL tumor cells were sorted into CD5 þ CD19 þ SP and non-SP fractions and used as target cells in IFN-g ELIspot assays. The results in Figure 4c showed that B-CLL-specific T cells generated by stimulation with hCD40L-activated autologous tumor cells were indeed able to recognize both the SP and non-SP subsets (Figure 4c) .
To further characterize the specificity and function of anti-B-CLL activity, we cloned B-CLL-reactive CD8 þ T cells from the T-cell lines generated from patient peripheral blood and tested their ability to recognize SP and non-SP tumor cells. In all, 9/13 clones recognized and produced IFN-g in response to both SP and non-SP B-CLL stimulation, but the level of reactivity (measured by IFN-g activity) induced by SP cells was significantly greater than by non-SP (P ¼ 0.005; Figure 4d ). Four clones recognized only SP cells, but no clones recognized only the non-SP fraction. Importantly, none of the clones showed background reactivity against allogeneic SP or non-SP B-CLL cells. These data suggest that immunization with hCD40L-activated B-CLL tumor cells can induce a T-cell response directed to epitopes shared by both SP and bulk tumor cells, and also to antigens differentially expressed by B-CLL SP tumor cells.
RHAMM-specific T cells specifically recognize B-CLL SP cells
Because the antigen specificity of patient-derived T-cell lines and T-cell clones was unknown, we analyzed whether B-CLL patient T cells could recognize previously described B-CLL antigens, including RHAMM, 19 survivin (BIRC5), 22 fibromodulin and murine double minute-2.
23, 24 As CD40 activation has previously been shown to increase antigen presentation 25 and upregulate tumor antigen expression on B-CLL cells, 26 we used reverse transcriptase-PCR amplification to see whether SP and non-SP B-CLL tumor cells express TAAs. Although survivin and fibromodulin expressions were detected in the SP fraction of B-CLL, RHAMM showed the greatest increase in preferential expression in the SP subset after exposure to soluble hCD40L ( Figure 5a ). As none of our cytotoxic T lymphocyte lines or T-cell clones in Figure 4 recognized RHAMM (data not shown), and because RHAMM was expressed in B-CLL SP tumor cells, we directly generated CD8 þ cytotoxic T lymphocyte cultures against an HLA-A2-restricted RHAMM peptide (ILSLELMKL) 27 using T cells from HLA-A2 þ vaccinated patients and autologous APCs. We successfully generated ILS-specific T cells from three of four donors as determined by IFN-g ELIspot using an HLA-A2-restricted peptide from MAGE-3 (FLW) as a negative control (Figure 5b ). To determine whether these patient-derived ILS-specific T cells could also recognize B-CLL SP cells, we separated hCD40 activated and non-activated SP and non-SP tumor cells and used them as the target cells in a IFN-g release ELIspot (Figure 5c ). We found that ILS-specific T cells had increased reactivity toward CD40-activated SP tumor cells when compared with non-activated, or CD40-activated non-SP or bulk tumor cells. This is consistent with the observation that RHAMM expression is elevated in SP cells after CD40L stimulation, allowing recognition by RHAMM-specific cytotoxic T lymphocyte. 
Elimination of SP B-CLL with hCD40L/IL-2 tumor vaccine AE Foster et al
To assess whether ILS-specific T cells recognizing RHAMM on B-CLL SP cells could selectively deplete these cells, we cocultured autologous ILS-specific T cells with B-CLL tumor cells and measured the change in SP frequency after 48 h. On exposure to autologous ILS-specific T cells, B-CLL SP cells were selectively depleted from the coculture when compared with non-SP cells, and their depletion was greater when the cells had been CD40 activated by CD40L (Figure 5d ). Together, these results suggest that increased expression of antigens, such as RHAMM, by the SP subset of B-CLL cells allows them to be preferentially recognized and eliminated when compared with the bulk tumor population, and that expression of these target antigens by B-CLL SP cells is increased after CD40 exposure.
Detection of RHAMM-specific T cells in PBMCs from subjects with B-CLL
The great majority of tumor cells express an array of TAAs, and hence the RHAMM antigen is likely only one of the many possible TAAs on B-CLL SP cells. Moreover, the ILS peptide is only one of the many potential T-cell epitopes even within the single RHAMM antigen. Nonetheless, if we were able to detect T cells specific for the RHAMM ILS peptide in the peripheral blood of patients after immunization with hCD40L/IL-2 tumor cells, and if the appearance of such cells was associated with a decline of SP cells in the circulation, then this would offer support for the concept of a specific anti-tumor immune response to B-CLL SP cells, and would help validate RHAMM as a TAA target suited to further exploration. We therefore examined PBMCs from two HLA-A2 patients (P1393 and P1335) who developed a measurable T-cell immune response to B-CLL SP cells that was associated with a decline in this tumor cell subset (Figures 6a and d) . In association with these anti-tumor effects, ILS-specific T cells that were absent before treatment increased during vaccination, and then subsided after treatment as the malignant SP cells returned (Figures 6b and e) . The ILS peptide of RHAMM expressed by B-CLL SP cells can therefore be a target of tumor-reactive T cells.
Discussion
We have identified a distinct CD5 þ CD19 þ SP phenotype in the peripheral blood of subjects with B-CLL. Although these B-CLL SP cells are resistant to fludarabine, which is a commonly used drug for the treatment of B-CLL, we show that this population can be targeted by T cells after vaccination with autologous tumor cells expressing hCD40L and IL-2. In association with the development of this immune response, there is a loss of malignant SP cells from the circulation, and their resurgence as immunity declines. T cells generated ex vivo from autologous CD40L-activated autologous tumor cells or by RHAMM peptide-pulsed TAPC specifically recognized autologous B-CLL SP cells and were able to eliminate this subset in coculture assays. Moreover, T cells with identical tumor-associated epitope specificity and activity were observed in vivo after immunization with the tumor vaccine, supporting an immune-mediated mechanism for the depletion of CD5 þ CD19 þ SP cells in these patients.
SP analysis has commonly been used to define normal and malignant cells with stem/progenitor cell-like characteristics. [6] [7] [8] [9] 11, 12 This has been a useful strategy for discriminating precursor cells from more 'mature' cells when surface markers are unknown or when antibodies are unavailable. In many cancer types, the association of the SP phenotype with high expression of ABC transporter proteins means that this subset of malignant cells also has primary drug resistance, and may therefore make a significant contribution to disease persistence or relapse. Such a contribution would be independent of any putative activity as a cancer progenitor cell. That a drug-resistant subpopulation does indeed exist in B-CLL was first suggested by the detection of ABCG2 expression by a minor subset of B-CLL tumor cells that was also associated with drug resistance. 28, 29 Nowakowski et al. 29 observed a dramatic increase in ABCG2 expressing B-CLL after treatment with pentostatin, cyclophosphamide and rituximab, suggesting that ABC transporter mechanisms are either directly responsible for drug resistance, or can reveal tumor cells with innate resistance to a variety of anticancer agents. de Wolf et al. 30 showed that human cell lines transgenically modified to express ABCG2 possessed increased resistance to anticancer nucleosides, including fludarabine, cladribine and clofarabine, suggesting that these agents are substrates of ABCG2 transporters. Other groups have shown that the SP phenotype also distinguishes tumor cells that are resistant to apoptosis through mechanisms not attributed to direct drug efflux.
12,21 Thus, Woodward et al. 12 showed that breast cancer tumor SP cells were enriched after radiation treatment, whereas Bleau et al. 21 showed that glioblastoma SP cells expressed higher levels of O6-methylguanine DNA methyltransferase, which was protective against temozolomide, which is not a ABCG2 substrate. In our cohort, we found ABCG2 expression to be heterogeneous, with some patient SP cells having clearly elevated expression, whereas SP cells from others were ABCG2 low (not shown). This may be due to inherent differences between patients, but also suggests that other ABC transporter family members may have a role in Hoechst and drug efflux in B-CLL. Unfortunately, we were unable to obtain sufficient samples to determine the in vivo effects of fludarabine on B-CLL SP cells have previously been detected in several other hematopoietic malignancies. 3, 4 In these disorders, the SP cells often differ in surface phenotype from bulk tumor cells, with higher expression of more primitive lineage markers (for example, CD34 and CD133). 3, 31 However, in primary tumor samples from B-CLL patients, we were unable to discern consistent differences between SP and bulk tumor cells by using a panel of progenitor cells (CD34, CD38 and CD133) and B-lineage monoclonal antibody markers (CD10, CD19, CD20, CD24, CD40, CD79b and CD127) (data not shown). Others have noted similar heterogeneous expression of progenitor and lineage markers in primary AML SP cells, 32 suggesting that a functional assay, such as SP, may more consistently detect rare but functionally chemoresistant/progenitor tumor cells in heterogeneous human hematological malignancies.
Despite the apparent inability of monoclonal antibody analysis to define a unique surface antigen phenotype on B-CLL SP cells, we were able to detect striking differences in expression of TAAs, including the antigen RHAMM. Analysis of SP and non-SP B-CLL cells before and after hCD40L stimulation showed that RHAMM expression was confined to the SP subset and was enhanced by CD40 activation. Giannopoulos et al. 26, 27 have also shown that RHAMM expression is CD40 activation dependent in B-CLL tumor cells, and that expression may correlate with aggressiveness of disease, although they did not analyze expression in B-CLL cell subsets. Although expression of RHAMM on tumor SP cells could be detected by patient cytotoxic T lymphocytes (Figure 5c ), we could also isolate T-cell clones from vaccinated patients that were not RHAMM specific, and several of these T-cell clones could nonetheless selectively recognize B-CLL SP cells rather than non-SP B-CLL (Figure 4d ). This result strongly suggests that other TAAs, 23, 24 in addition to RHAMM, are differentially expressed between SP and non-SP cells, and that vaccination of patients with CD40L-expressing B-CLL tumor cells can induce an immune response directed against the minor SP subset of cells that upregulate TAAs, such as RHAMM, upon CD40 activation. The recognition and elimination of CD40L-activated SP cells by RHAMMspecific T cells in vitro, coupled with the appearance of RHAMM (ILS) peptide-specific T cells in the peripheral blood as the malignant SP declines, supports our suggestion even though RHAMM is likely only one of the multiple TAAs expressed by SP cells. It is possible that other immunological differences between SP and non-SP could account for the selective elimination of B-CLL SP cells; however, we have not found significant differences in cell surface expression of MHC class I, costimulatory molecules (for example, CD80 and CD86) or expression of immune suppressive cytokines such as IL-10 (not shown). In this study, the anti-SP B-CLL T-cell response that we described is lost 4-6 weeks after vaccine administration ceased. There are a variety of immunological deficiencies in B-CLL patients, including suboptimal antigen presentation and synapse formation, 25, 33, 34 elevated levels of regulatory T cells 17, 35 and direct immune suppression through B-CLL-expressed ligands, 36 which likely contribute to the short persistence of T cells after vaccination and only the transient elimination of B-CLL SP tumor cells. Nonetheless, data from this study suggest that a sequential combination of chemotherapy to debulk the disease, and immunotherapy to target chemoresistant B-CLL tumor cells may help prolong disease control.
